Valneva, a specialty vaccine company, today announced the start of booster vaccinations in adult participants from its Phase 3 pivotal... View Article
OSE Immunotherapeutics receives first notice of allowance of a patent for use of Tedopi® after failure with PD-1 or PD-L1... View Article
Preliminary laboratory studies demonstrate that three doses of Valneva’s inactivated COVID-19 vaccine candidate VLA2001 induced neutralization of the Omicron variant.... View Article